Pulse Intravenous Methylprednisolone for Resistant Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis
Allergic bronchopulmonary aspergillosis (ABPA) results from a hypersensitivity response to Aspergillus fumigatus. It is seen in a number of chronic respiratory conditions, particularly in association with cystic fibrosis (CF). Oral corticosteroids and itraconazole represent the mainstay of treatment...
Gespeichert in:
| Veröffentlicht in: | Pediatric pulmonology 2006-02, Vol.41 (2), p.164-170 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 170 |
|---|---|
| container_issue | 2 |
| container_start_page | 164 |
| container_title | Pediatric pulmonology |
| container_volume | 41 |
| creator | Thomson, Janine M. Wesley, Alison Byrnes, Catherine A. Nixon, Gillian M. |
| description | Allergic bronchopulmonary aspergillosis (ABPA) results from a hypersensitivity response to Aspergillus fumigatus. It is seen in a number of chronic respiratory conditions, particularly in association with cystic fibrosis (CF). Oral corticosteroids and itraconazole represent the mainstay of treatment. There is evidence for the use of pulse methylprednisolone in other respiratory conditions as well as a number of inflammatory conditions. This is the first reported use of pulse intravenous methylprednisolone in the treatment of ABPA in CF. We present the clinical course of four children with CF and severe ABPA, in whom pulse methyprednisolone was used to manage the disease because of relapses or marked side effects on high‐dose oral corticosteroids. Methylprednisolone pulses achieved disease control in 3 of the 4 children. However, troublesome side effects were experienced, in some cases necessitating discontinuation of therapy. Pulse methylprednisolone may represent a treatment option for children with CF and ABPA, where ABPA fails to respond adequately to routine therapy. Pediatr Pulmonol. © 2005 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/ppul.20333 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67600251</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67600251</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3953-7e8fe7ddf49292dc565e4e2aee07eb592ea9359bbb55f5be47b3afc9c3af81453</originalsourceid><addsrcrecordid>eNp9kUFv1DAQhS0EotvChR-AfIEDUoodx3F8XFZ0W7SFFaLq0XKcCTU4drATyv57vOxCb1xsyfPNvHnPCL2g5JwSUr4dx9mdl4Qx9ggtKJGyIJWsH6NFIzgv6qZmJ-g0pW-E5JqkT9EJrRkVoiwXaNjOLgG-8lPUP8GHOeFrmO52bozQeZuCCx5wHyL-DMmmSfsJL52D-NUa_C4Gb-5Clh-C13GHl2ncV5wLmcXW49UuTRm8sG3cPz1DT3qd9Z4f7zN0c_H-y-qy2HxaX62Wm8IwyVkhoOlBdF1fyVKWneE1hwpKDUAEtFyWoCXjsm1bznveQiVapnsjTT4bWnF2hl4f5o4x_JghTWqwyYBz2kO2qGpR5-A4zeCbA2jyfilCr8Zoh2xFUaL24ap9uOpPuBl-eZw6twN0D-gxzQy8OgI6Ge36qL2x6YETnNV1U2WOHrh762D3H0m13d5s_ooXh578CfDrX4-O37MbJri6_bhWnF7eynX1QV2z3yWipI4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67600251</pqid></control><display><type>article</type><title>Pulse Intravenous Methylprednisolone for Resistant Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Thomson, Janine M. ; Wesley, Alison ; Byrnes, Catherine A. ; Nixon, Gillian M.</creator><creatorcontrib>Thomson, Janine M. ; Wesley, Alison ; Byrnes, Catherine A. ; Nixon, Gillian M.</creatorcontrib><description>Allergic bronchopulmonary aspergillosis (ABPA) results from a hypersensitivity response to Aspergillus fumigatus. It is seen in a number of chronic respiratory conditions, particularly in association with cystic fibrosis (CF). Oral corticosteroids and itraconazole represent the mainstay of treatment. There is evidence for the use of pulse methylprednisolone in other respiratory conditions as well as a number of inflammatory conditions. This is the first reported use of pulse intravenous methylprednisolone in the treatment of ABPA in CF. We present the clinical course of four children with CF and severe ABPA, in whom pulse methyprednisolone was used to manage the disease because of relapses or marked side effects on high‐dose oral corticosteroids. Methylprednisolone pulses achieved disease control in 3 of the 4 children. However, troublesome side effects were experienced, in some cases necessitating discontinuation of therapy. Pulse methylprednisolone may represent a treatment option for children with CF and ABPA, where ABPA fails to respond adequately to routine therapy. Pediatr Pulmonol. © 2005 Wiley‐Liss, Inc.</description><identifier>ISSN: 8755-6863</identifier><identifier>EISSN: 1099-0496</identifier><identifier>DOI: 10.1002/ppul.20333</identifier><identifier>PMID: 16317722</identifier><identifier>CODEN: PEPUES</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>allergic bronchopulmonary aspergillosis ; Antifungal Agents - therapeutic use ; Aspergillosis, Allergic Bronchopulmonary - complications ; Aspergillosis, Allergic Bronchopulmonary - drug therapy ; Aspergillus - drug effects ; Aspergillus - isolation & purification ; Biological and medical sciences ; Child ; children ; corticosteroid ; cystic fibrosis ; Cystic Fibrosis - complications ; Cystic Fibrosis - drug therapy ; Drug Resistance, Fungal ; Errors of metabolism ; Female ; Follow-Up Studies ; Glucocorticoids - administration & dosage ; Glucocorticoids - therapeutic use ; Human mycoses ; Humans ; Infant ; Infectious diseases ; Injections, Intravenous ; Itraconazole - therapeutic use ; Male ; Medical sciences ; Metabolic diseases ; methylprednisolone ; Methylprednisolone - administration & dosage ; Methylprednisolone - therapeutic use ; Miscellaneous hereditary metabolic disorders ; Miscellaneous mycoses ; Mycoses ; Pneumology ; pulse therapy ; Pulse Therapy, Drug ; Sputum - microbiology</subject><ispartof>Pediatric pulmonology, 2006-02, Vol.41 (2), p.164-170</ispartof><rights>Copyright © 2005 Wiley‐Liss, Inc.</rights><rights>2006 INIST-CNRS</rights><rights>(c) 2005 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3953-7e8fe7ddf49292dc565e4e2aee07eb592ea9359bbb55f5be47b3afc9c3af81453</citedby><cites>FETCH-LOGICAL-c3953-7e8fe7ddf49292dc565e4e2aee07eb592ea9359bbb55f5be47b3afc9c3af81453</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fppul.20333$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fppul.20333$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17536684$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16317722$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thomson, Janine M.</creatorcontrib><creatorcontrib>Wesley, Alison</creatorcontrib><creatorcontrib>Byrnes, Catherine A.</creatorcontrib><creatorcontrib>Nixon, Gillian M.</creatorcontrib><title>Pulse Intravenous Methylprednisolone for Resistant Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis</title><title>Pediatric pulmonology</title><addtitle>Pediatr. Pulmonol</addtitle><description>Allergic bronchopulmonary aspergillosis (ABPA) results from a hypersensitivity response to Aspergillus fumigatus. It is seen in a number of chronic respiratory conditions, particularly in association with cystic fibrosis (CF). Oral corticosteroids and itraconazole represent the mainstay of treatment. There is evidence for the use of pulse methylprednisolone in other respiratory conditions as well as a number of inflammatory conditions. This is the first reported use of pulse intravenous methylprednisolone in the treatment of ABPA in CF. We present the clinical course of four children with CF and severe ABPA, in whom pulse methyprednisolone was used to manage the disease because of relapses or marked side effects on high‐dose oral corticosteroids. Methylprednisolone pulses achieved disease control in 3 of the 4 children. However, troublesome side effects were experienced, in some cases necessitating discontinuation of therapy. Pulse methylprednisolone may represent a treatment option for children with CF and ABPA, where ABPA fails to respond adequately to routine therapy. Pediatr Pulmonol. © 2005 Wiley‐Liss, Inc.</description><subject>allergic bronchopulmonary aspergillosis</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Aspergillosis, Allergic Bronchopulmonary - complications</subject><subject>Aspergillosis, Allergic Bronchopulmonary - drug therapy</subject><subject>Aspergillus - drug effects</subject><subject>Aspergillus - isolation & purification</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>children</subject><subject>corticosteroid</subject><subject>cystic fibrosis</subject><subject>Cystic Fibrosis - complications</subject><subject>Cystic Fibrosis - drug therapy</subject><subject>Drug Resistance, Fungal</subject><subject>Errors of metabolism</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glucocorticoids - administration & dosage</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Human mycoses</subject><subject>Humans</subject><subject>Infant</subject><subject>Infectious diseases</subject><subject>Injections, Intravenous</subject><subject>Itraconazole - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>methylprednisolone</subject><subject>Methylprednisolone - administration & dosage</subject><subject>Methylprednisolone - therapeutic use</subject><subject>Miscellaneous hereditary metabolic disorders</subject><subject>Miscellaneous mycoses</subject><subject>Mycoses</subject><subject>Pneumology</subject><subject>pulse therapy</subject><subject>Pulse Therapy, Drug</subject><subject>Sputum - microbiology</subject><issn>8755-6863</issn><issn>1099-0496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUFv1DAQhS0EotvChR-AfIEDUoodx3F8XFZ0W7SFFaLq0XKcCTU4drATyv57vOxCb1xsyfPNvHnPCL2g5JwSUr4dx9mdl4Qx9ggtKJGyIJWsH6NFIzgv6qZmJ-g0pW-E5JqkT9EJrRkVoiwXaNjOLgG-8lPUP8GHOeFrmO52bozQeZuCCx5wHyL-DMmmSfsJL52D-NUa_C4Gb-5Clh-C13GHl2ncV5wLmcXW49UuTRm8sG3cPz1DT3qd9Z4f7zN0c_H-y-qy2HxaX62Wm8IwyVkhoOlBdF1fyVKWneE1hwpKDUAEtFyWoCXjsm1bznveQiVapnsjTT4bWnF2hl4f5o4x_JghTWqwyYBz2kO2qGpR5-A4zeCbA2jyfilCr8Zoh2xFUaL24ap9uOpPuBl-eZw6twN0D-gxzQy8OgI6Ge36qL2x6YETnNV1U2WOHrh762D3H0m13d5s_ooXh578CfDrX4-O37MbJri6_bhWnF7eynX1QV2z3yWipI4</recordid><startdate>200602</startdate><enddate>200602</enddate><creator>Thomson, Janine M.</creator><creator>Wesley, Alison</creator><creator>Byrnes, Catherine A.</creator><creator>Nixon, Gillian M.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200602</creationdate><title>Pulse Intravenous Methylprednisolone for Resistant Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis</title><author>Thomson, Janine M. ; Wesley, Alison ; Byrnes, Catherine A. ; Nixon, Gillian M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3953-7e8fe7ddf49292dc565e4e2aee07eb592ea9359bbb55f5be47b3afc9c3af81453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>allergic bronchopulmonary aspergillosis</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Aspergillosis, Allergic Bronchopulmonary - complications</topic><topic>Aspergillosis, Allergic Bronchopulmonary - drug therapy</topic><topic>Aspergillus - drug effects</topic><topic>Aspergillus - isolation & purification</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>children</topic><topic>corticosteroid</topic><topic>cystic fibrosis</topic><topic>Cystic Fibrosis - complications</topic><topic>Cystic Fibrosis - drug therapy</topic><topic>Drug Resistance, Fungal</topic><topic>Errors of metabolism</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glucocorticoids - administration & dosage</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Human mycoses</topic><topic>Humans</topic><topic>Infant</topic><topic>Infectious diseases</topic><topic>Injections, Intravenous</topic><topic>Itraconazole - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>methylprednisolone</topic><topic>Methylprednisolone - administration & dosage</topic><topic>Methylprednisolone - therapeutic use</topic><topic>Miscellaneous hereditary metabolic disorders</topic><topic>Miscellaneous mycoses</topic><topic>Mycoses</topic><topic>Pneumology</topic><topic>pulse therapy</topic><topic>Pulse Therapy, Drug</topic><topic>Sputum - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thomson, Janine M.</creatorcontrib><creatorcontrib>Wesley, Alison</creatorcontrib><creatorcontrib>Byrnes, Catherine A.</creatorcontrib><creatorcontrib>Nixon, Gillian M.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric pulmonology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thomson, Janine M.</au><au>Wesley, Alison</au><au>Byrnes, Catherine A.</au><au>Nixon, Gillian M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pulse Intravenous Methylprednisolone for Resistant Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis</atitle><jtitle>Pediatric pulmonology</jtitle><addtitle>Pediatr. Pulmonol</addtitle><date>2006-02</date><risdate>2006</risdate><volume>41</volume><issue>2</issue><spage>164</spage><epage>170</epage><pages>164-170</pages><issn>8755-6863</issn><eissn>1099-0496</eissn><coden>PEPUES</coden><abstract>Allergic bronchopulmonary aspergillosis (ABPA) results from a hypersensitivity response to Aspergillus fumigatus. It is seen in a number of chronic respiratory conditions, particularly in association with cystic fibrosis (CF). Oral corticosteroids and itraconazole represent the mainstay of treatment. There is evidence for the use of pulse methylprednisolone in other respiratory conditions as well as a number of inflammatory conditions. This is the first reported use of pulse intravenous methylprednisolone in the treatment of ABPA in CF. We present the clinical course of four children with CF and severe ABPA, in whom pulse methyprednisolone was used to manage the disease because of relapses or marked side effects on high‐dose oral corticosteroids. Methylprednisolone pulses achieved disease control in 3 of the 4 children. However, troublesome side effects were experienced, in some cases necessitating discontinuation of therapy. Pulse methylprednisolone may represent a treatment option for children with CF and ABPA, where ABPA fails to respond adequately to routine therapy. Pediatr Pulmonol. © 2005 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>16317722</pmid><doi>10.1002/ppul.20333</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 8755-6863 |
| ispartof | Pediatric pulmonology, 2006-02, Vol.41 (2), p.164-170 |
| issn | 8755-6863 1099-0496 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67600251 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | allergic bronchopulmonary aspergillosis Antifungal Agents - therapeutic use Aspergillosis, Allergic Bronchopulmonary - complications Aspergillosis, Allergic Bronchopulmonary - drug therapy Aspergillus - drug effects Aspergillus - isolation & purification Biological and medical sciences Child children corticosteroid cystic fibrosis Cystic Fibrosis - complications Cystic Fibrosis - drug therapy Drug Resistance, Fungal Errors of metabolism Female Follow-Up Studies Glucocorticoids - administration & dosage Glucocorticoids - therapeutic use Human mycoses Humans Infant Infectious diseases Injections, Intravenous Itraconazole - therapeutic use Male Medical sciences Metabolic diseases methylprednisolone Methylprednisolone - administration & dosage Methylprednisolone - therapeutic use Miscellaneous hereditary metabolic disorders Miscellaneous mycoses Mycoses Pneumology pulse therapy Pulse Therapy, Drug Sputum - microbiology |
| title | Pulse Intravenous Methylprednisolone for Resistant Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T17%3A59%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pulse%20Intravenous%20Methylprednisolone%20for%20Resistant%20Allergic%20Bronchopulmonary%20Aspergillosis%20in%20Cystic%20Fibrosis&rft.jtitle=Pediatric%20pulmonology&rft.au=Thomson,%20Janine%20M.&rft.date=2006-02&rft.volume=41&rft.issue=2&rft.spage=164&rft.epage=170&rft.pages=164-170&rft.issn=8755-6863&rft.eissn=1099-0496&rft.coden=PEPUES&rft_id=info:doi/10.1002/ppul.20333&rft_dat=%3Cproquest_cross%3E67600251%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67600251&rft_id=info:pmid/16317722&rfr_iscdi=true |